OBJECTIVE: Multiple studies in sepsis have demonstrated that elevated troponin is associated with poor outcome. The elevated troponin in this situation is thought to be secondary to microthrombi. We hypothesized that recombinant human activated protein C (APC) treatment would improve outcomes in severe sepsis patients who have elevated troponin. METHODS:Patients with severe sepsis by consensus criteria in a university ICU were divided into a troponin elevated group (cTnI+) and a normal troponin (cTnI(-)) group. Outcome was compared using Fisher's exact test. APACHE[Symbol: see text]II and MODS were calculated by standard methods. PATIENTS: We identified 105 patients with severe sepsis and troponin measured, of which 48 (46%) were in the cTnI+ group. The two groups were similar in terms of age and other comorbid conditions. RESULTS: APACHE II (28+/-8 vs. 25+/-8) was slightly higher and MODS (11+/-4 vs. 9+/-3) was significantly higher in the cTnI+ group. Mortality was 52% (25/48) in cTnI+ group and 30% (17/57) in cTnI(-) group. Mortality was 30% in cTnI+ patients treated with APC and 72% in untreated cTnI+ patients. CONCLUSIONS:Patients with severe sepsis who have elevated troponin have increased mortality. In patients with severe sepsis who have elevated troponin, treatment withAPC improves outcome. Further study is needed to determine whether troponin can serve as a simple, readily available marker to identify which patients with severe sepsis will benefit from APC.
RCT Entities:
OBJECTIVE: Multiple studies in sepsis have demonstrated that elevated troponin is associated with poor outcome. The elevated troponin in this situation is thought to be secondary to microthrombi. We hypothesized that recombinant human activated protein C (APC) treatment would improve outcomes in severe sepsispatients who have elevated troponin. METHODS:Patients with severe sepsis by consensus criteria in a university ICU were divided into a troponin elevated group (cTnI+) and a normal troponin (cTnI(-)) group. Outcome was compared using Fisher's exact test. APACHE[Symbol: see text]II and MODS were calculated by standard methods. PATIENTS: We identified 105 patients with severe sepsis and troponin measured, of which 48 (46%) were in the cTnI+ group. The two groups were similar in terms of age and other comorbid conditions. RESULTS: APACHE II (28+/-8 vs. 25+/-8) was slightly higher and MODS (11+/-4 vs. 9+/-3) was significantly higher in the cTnI+ group. Mortality was 52% (25/48) in cTnI+ group and 30% (17/57) in cTnI(-) group. Mortality was 30% in cTnI+ patients treated with APC and 72% in untreated cTnI+ patients. CONCLUSIONS:Patients with severe sepsis who have elevated troponin have increased mortality. In patients with severe sepsis who have elevated troponin, treatment with APC improves outcome. Further study is needed to determine whether troponin can serve as a simple, readily available marker to identify which patients with severe sepsis will benefit from APC.
Authors: R L Wilder; R Lafyatis; A B Roberts; J P Case; G K Kumkumian; H Sano; M B Sporn; E F Remmers Journal: Ann N Y Acad Sci Date: 1990 Impact factor: 5.691
Authors: Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay Journal: Crit Care Med Date: 2003-04 Impact factor: 7.598
Authors: Peter Ammann; Marco Maggiorini; Osmund Bertel; Edgar Haenseler; Helen I Joller-Jemelka; Erwin Oechslin; Elisabeth I Minder; Hans Rickli; Thomas Fehr Journal: J Am Coll Cardiol Date: 2003-06-04 Impact factor: 24.094
Authors: E Wesley Ely; Pierre-François Laterre; Derek C Angus; Jeffrey D Helterbrand; Howard Levy; Jean-François Dhainaut; Jean-Louis Vincent; William L Macias; Gordon R Bernard Journal: Crit Care Med Date: 2003-01 Impact factor: 7.598
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Johan Groeneveld; Goran Hedenstierna; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Philipp Metnitz; Jerme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2008-01-31 Impact factor: 17.440
Authors: Francis Bessière; Safia Khenifer; Julie Dubourg; Isabelle Durieu; Jean-Christophe Lega Journal: Intensive Care Med Date: 2013-04-18 Impact factor: 17.440
Authors: Helge Røsjø; Marjut Varpula; Tor-Arne Hagve; Sari Karlsson; Esko Ruokonen; Ville Pettilä; Torbjørn Omland Journal: Intensive Care Med Date: 2010-10-12 Impact factor: 17.440
Authors: Ali Jendoubi; Salma Jerbi; Elaa Maamar; Ahmed Abbess; Zied Samoud; Lamia Kanzari; Ilhem Boutiba; Salma Ghedira; Mohamed Houissa Journal: Indian J Crit Care Med Date: 2019-07
Authors: Saraschandra Vallabhajosyula; Ankit Sakhuja; Jeffrey B Geske; Mukesh Kumar; Joseph T Poterucha; Rahul Kashyap; Kianoush Kashani; Allan S Jaffe; Jacob C Jentzer Journal: J Am Heart Assoc Date: 2017-09-09 Impact factor: 5.501